Abstract
During the last decade there has been a growing interest towards the modulation of the cannabinoid CB1 receptor. The identification of CB1 cannabinoid receptor antagonists has been one of the major advances in cannabinoid research. Thus, the development of these ligands has opened new therapeutic applications. Since the discovery of the first cannabinoid receptor antagonist, rimonabant, by Sanofi in 1994, a large number of structural variations within this chemical series of 1,5-diarylpyrazoles have been described. So far, all attempts to identify novel structures for CB1 antagonists have been based on one or more pharmacophoric elements of the rimonabant structure. The advanced clinical trials of rimonabant confirm the therapeutic potential value of CB1 antagonists for the treatment of obesity. In addition, the results of pharmacological and clinical studies reveal other effective pharmacotherapeutic applications. The current review will mainly focus on the structure-activity relationships that have been established for antagonists/inverse agonists that bind to the CB1 cannabinoid receptors and on their therapeutic applications.
Keywords: Cannabinoid, antagonist, CB1, rimonabant, endocannabinoid
Current Topics in Medicinal Chemistry
Title: CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Volume: 8 Issue: 3
Author(s): Nadine Jagerovic, Cristina Fernandez-Fernandez and Pilar Goya
Affiliation:
Keywords: Cannabinoid, antagonist, CB1, rimonabant, endocannabinoid
Abstract: During the last decade there has been a growing interest towards the modulation of the cannabinoid CB1 receptor. The identification of CB1 cannabinoid receptor antagonists has been one of the major advances in cannabinoid research. Thus, the development of these ligands has opened new therapeutic applications. Since the discovery of the first cannabinoid receptor antagonist, rimonabant, by Sanofi in 1994, a large number of structural variations within this chemical series of 1,5-diarylpyrazoles have been described. So far, all attempts to identify novel structures for CB1 antagonists have been based on one or more pharmacophoric elements of the rimonabant structure. The advanced clinical trials of rimonabant confirm the therapeutic potential value of CB1 antagonists for the treatment of obesity. In addition, the results of pharmacological and clinical studies reveal other effective pharmacotherapeutic applications. The current review will mainly focus on the structure-activity relationships that have been established for antagonists/inverse agonists that bind to the CB1 cannabinoid receptors and on their therapeutic applications.
Export Options
About this article
Cite this article as:
Jagerovic Nadine, Fernandez-Fernandez Cristina and Goya Pilar, CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications, Current Topics in Medicinal Chemistry 2008; 8 (3) . https://dx.doi.org/10.2174/156802608783498050
DOI https://dx.doi.org/10.2174/156802608783498050 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Experimental Model Considerations for the Study of Protein-Energy Malnutrition Co-Existing with Ischemic Brain Injury
Current Neurovascular Research Structure-Function Relationships of Iodinated Contrast Media and Risk of Nephrotoxicity
Current Medicinal Chemistry Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Serum Cystatin C-A Useful Endogenous Marker of Renal Function in Intensive Care Unit Patients at Risk for or with Acute Renal Failure?
Current Medicinal Chemistry Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Inflammatory Mediators and the Failing Heart: A Translational Approach
Current Molecular Medicine Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression
Current Pharmaceutical Design Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Utility of the Electrocardiogram in Drug Overdose and Poisoning: Theoretical Considerations and Clinical Implications
Current Cardiology Reviews Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Vascular effects of flavonoids
Current Medicinal Chemistry An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism